Jiangsu Yahong Meditech Co., Ltd. Class ASSE: 688176

Announcement on Voluntarily Disclosure of Phase II Clinical Trial Results of Oral APL-1202 Combined with Tislelizumab in Neoadjuvant Therapy for Muscle-invasive Bladder Cancer

· Issued by Jiangsu Yahong Meditech Co., Ltd. Class A via Shanghai Stock Exchange
Announcement on Voluntarily Disclosure of Phase II Clinical Trial Results of Oral APL-1202 Combined with Tislelizumab in Neoadjuvant Therapy for Muscle-invasive Bladder Cancer

The abstract is for reference only. Please refer to the full text of the announcement on the very day.

Link of Full Text for Reference:
View Attachment

Company analysis